1. IARC. List of Classifications - IARC Monographs on the identification of carcinogenic hazards to humans. 2022. https://monographs.iarc.who.int/list-of-classifications
2. International Council for Harmonisation. Assessment and control of DNA reactive (Mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7(R1).; 2017. https://database.ich.org/sites/default/files/M7_R1_Guideline.pdf
3. Drawing a line: where might the cohort of concern end?;Ponting;Org Process Res Dev,2023
4. Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products;Snodin;Regul Toxicol Pharmacol,2019
5. NDMA impurity in valsartan and other pharmaceutical products: analytical methods for the determination of N-nitrosamines;Parr;J Pharm Biomed Anal,2019